KSQ-004
- Generic Name
- KSQ-004
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Select Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 141
- Registration Number
- NCT06598371
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath